ADMA ADMA Bio: Forward P/S Multiple
ADMA Biologics has maximized the capacity of its plasma processing plants while expanding its network of raw material collection centers. Revenues are based on the supply of antibodies to hospitals for the therapy of patients with immunodeficiency. The forward P/S trend demonstrates the business valuation dynamics, where the value 5.30 represents the current metric. A proprietary, state-of-the-art complex in Florida guarantees supply stability.
Metric breakdowns and analytics for ADMA Corp (ADMA)
- current price and projected stock value:
- company stock capitalization data:
- issuer book value statistics:
- issuer credit burden and liquidity indicators:
- financial results and valuation multiples details:
ADMA - Company Net Income|Expected Profit ADMA Biologics|ADMA - Price to Earnings Ratio|Future Price to Earnings ADMA Bio|ADMA - Price to Earnings Adjusted for Growth Rate|EV/EBITDA Multiple ADMA Corp|ADMA - Operating profit before depreciation charges|Net earnings per share (EPS TTM) ADMA Biologics|ADMA - Net earnings per share for the last four quarters|Quarterly EPS earnings growth admabiologics.com|ADMA - Net earnings per share growth this year|Net earnings per share growth forecast for next year ADMA Biologics
- sales and revenue indicators:
Summary company analysis:ADMA Biologics, Inc. ADMA
Amidst fierce competition for donor resources and the threat of synthetic plasma analogs, ADMA Biologics faces significant pressure on its market position. The forward price-to-sales valuation trend reflects the ratio of current market capitalization to projected revenue, allowing investors to filter out volatility and determine whether the capital is overvalued relative to real revenue growth prospects.
Who ADMA Biologics competes with
Forward P/S Multiple ARGX (argenx)|BioNTech Inc. (BNTX) - Market Cap to Future Revenue Ratio|Abivax Corp - Forward P/S Multiple|PTGX - Forward P/S Multiple|IMVT: Forward P/S Multiple|Market Cap to Projected Revenue KNSA|Price-to-Projected Revenue Ratio Grifols|Forward Price-to-Revenue Multiple Adaptive Biotech (ADPT)|Forward P/S Multiple CLDX|Forward P/S Multiple Aurinia Corp (AUPH)|BioCryst - Forward Price-to-Revenue Multiple|Forward Price to Sales VERA|Dianthus Therapeutics, Inc. - Forward P/S Multiple|PHVS: Price-to-Projected Revenue Ratio|ABCL: Forward P/S Multiple|TRML - Market Cap to Expected Sales Ratio|Price-to-Projected Revenue Ratio Precigen, Inc.|Market Cap to Future Revenue Ratio pharming.com PHAR|Price-to-Projected Revenue Ratio Nektar Therapeutics Inc. (NKTR)|Price-to-Projected Revenue Ratio UPB (Upstream Bio, Inc.)|Price-to-Projected Revenue Ratio Zenas Biopharma, Inc. ZBIO|Immunome Bio (IMNM) - Market Cap to Future Revenue Ratio|Gossamer Bio, Inc. - Forward P/S Multiple|Projected Price to Revenue kalvista.com (KALV)|SEPN: Forward P/S Multiple|PVLA - Market Cap to Expected Sales Ratio|SVRA (Savara Corp) - Forward P/S Multiple|Forward Price-to-Revenue Multiple Rigel Corp (RIGL)|Price-to-Projected Revenue Ratio AnaptysBio, Inc. (ANAB)|Market Cap to Expected Sales Ratio astriatx.com|Forward P/S Multiple ENGN (enGene)|Forward P/S Multiple RAPT Therapeutics Inc. RAPT|Aerovate - Forward P/S Multiple|ACRS (Aclaris Therapeutics, Inc) - Market Cap to Projected Revenue|Kyverna Therapeutics (KYTX) - Price-to-Projected Revenue Ratio|Forward Price-to-Revenue Multiple tizianalifesciences.com|CABA (Cabaletta Bio) - Forward P/S Multiple|Forward P/S Multiple Ventyx Biosciences Inc.|Price-to-Projected Revenue Ratio Theratechnologies Inc (THTX)|AVTX: Future Price to Revenue|Forward P/S Multiple ELDN (Eledon Pharmaceuticals)|Forward Price to Sales AGEN|Climb Bio - Forward P/S Multiple|ZURA - Forward P/S Multiple|aTyr (ATYR) - Price-to-Projected Revenue Ratio|Adagene Inc. - Forward Price to Sales|Price-to-Projected Revenue Ratio ImageneBio|Forward Price-to-Revenue Multiple Shattuck Therapeutics (STTK)|Forward P/S Multiple EQ|Forward P/S Multiple connectbiopharm.com (CNTB)|Immunic - Forward Price-to-Revenue Multiple|Forward Price to Sales ATRA|InflaRx GmbH - Forward P/S Multiple|Market Cap to Expected Sales Ratio x4pharma.com XFOR|adicetbio.com (ACET) - Price-to-Projected Revenue Ratio|Forward Price-to-Revenue Multiple Celularity|Price-to-Projected Revenue Ratio INmune Bio Corp|Forward Price-to-Revenue Multiple Barinthus Biotherapeutics Corp (BRNS)|Forward Price-to-Revenue Multiple KZR (Kezar Life Sciences)|Forward P/S Multiple sabbiotherapeutics.com (SABS)|Price-to-Projected Revenue Ratio Akari Therapeutics Plc AKTX|ENLV: Market Cap to Projected Revenue|Q32 Bio Corp - Forward P/S Multiple|Market Cap to Future Revenue Ratio GeoVax Corp|EDSA: Forward P/S Multiple|ibioinc.com (IBIO) - Forward P/S Multiple|CARM (Carisma Therapeutics Inc) - Forward P/S Multiple|Market Cap to Projected Revenue XTLB (XTL Biopharmaceuticals Ltd)|Price-to-Projected Revenue Ratio Bolt Biotherapeutics (BOLT)|Forward Price-to-Revenue Multiple hcwbiologics.com HCWB|Forward P/S Multiple APVO (Aptevo Therapeutics Inc.)|Forward P/S Multiple AIM ImmunoTech, Inc. AIM|ADTX: Forward Price-to-Revenue Multiple|Forward Price to Sales GRI (GRI Bio Inc)|XRTX: Forward P/S Multiple|HIND (Vyome Therapeutics) - Price-to-Projected Revenue Ratio|REVB (Revelation Biosciences) - Forward P/S Multiple|indaptusrx.com (INDP) - Market Cap to Expected Sales Ratio|Price-to-Projected Revenue Ratio Scinai Immunotherapeutics Ltd. (SCNI)|CALI - Market Cap to Future Revenue Ratio|Price-to-Projected Revenue Ratio Affimed N.V. AFMD|Allakos Inc - Price-to-Projected Revenue Ratio|HOOK - Price-to-Projected Revenue Ratio|Market Cap to Future Revenue Ratio IGM Biosciences, Inc.|ITOS: Forward P/S Multiple|Projected Price to Revenue Ocean Biomedical Inc OCEA|TCBP (TC BioPharm (Holdings) PLC) - Forward P/S Multiple|Third Harmonic Bio Inc (THRD) - Market Cap to Expected Sales Ratio
